These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 20920668)

  • 41. An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model.
    Seburn KL; Nangle LA; Cox GA; Schimmel P; Burgess RW
    Neuron; 2006 Sep; 51(6):715-26. PubMed ID: 16982418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutation analysis of the small heat shock protein 27 gene in chinese patients with Charcot-Marie-Tooth disease.
    Tang B; Liu X; Zhao G; Luo W; Xia K; Pan Q; Cai F; Hu Z; Zhang C; Chen B; Zhang F; Shen L; Zhang R; Jiang H
    Arch Neurol; 2005 Aug; 62(8):1201-7. PubMed ID: 16087758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy.
    Achilli F; Bros-Facer V; Williams HP; Banks GT; AlQatari M; Chia R; Tucci V; Groves M; Nickols CD; Seburn KL; Kendall R; Cader MZ; Talbot K; van Minnen J; Burgess RW; Brandner S; Martin JE; Koltzenburg M; Greensmith L; Nolan PM; Fisher EM
    Dis Model Mech; 2009; 2(7-8):359-73. PubMed ID: 19470612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease.
    Latour P; Thauvin-Robinet C; Baudelet-Méry C; Soichot P; Cusin V; Faivre L; Locatelli MC; Mayençon M; Sarcey A; Broussolle E; Camu W; David A; Rousson R
    Am J Hum Genet; 2010 Jan; 86(1):77-82. PubMed ID: 20045102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy.
    Bervoets S; Wei N; Erfurth ML; Yusein-Myashkova S; Ermanoska B; Mateiu L; Asselbergh B; Blocquel D; Kakad P; Penserga T; Thomas FP; Guergueltcheva V; Tournev I; Godenschwege T; Jordanova A; Yang XL
    Nat Commun; 2019 Nov; 10(1):5045. PubMed ID: 31695036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compound heterozygosity for loss-of-function FARSB variants in a patient with classic features of recessive aminoacyl-tRNA synthetase-related disease.
    Antonellis A; Oprescu SN; Griffin LB; Heider A; Amalfitano A; Innis JW
    Hum Mutat; 2018 Jun; 39(6):834-840. PubMed ID: 29573043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biallelic KARS pathogenic variants cause an early-onset progressive leukodystrophy.
    Itoh M; Dai H; Horike SI; Gonzalez J; Kitami Y; Meguro-Horike M; Kuki I; Shimakawa S; Yoshinaga H; Ota Y; Okazaki T; Maegaki Y; Nabatame S; Okazaki S; Kawawaki H; Ueno N; Goto YI; Kato Y
    Brain; 2019 Mar; 142(3):560-573. PubMed ID: 30715177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A humanized yeast model reveals dominant-negative properties of neuropathy-associated alanyl-tRNA synthetase mutations.
    Meyer-Schuman R; Marte S; Smith TJ; Feely SME; Kennerson M; Nicholson G; Shy ME; Koutmou KS; Antonellis A
    Hum Mol Genet; 2023 Jun; 32(13):2177-2191. PubMed ID: 37010095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V.
    Antonellis A; Ellsworth RE; Sambuughin N; Puls I; Abel A; Lee-Lin SQ; Jordanova A; Kremensky I; Christodoulou K; Middleton LT; Sivakumar K; Ionasescu V; Funalot B; Vance JM; Goldfarb LG; Fischbeck KH; Green ED
    Am J Hum Genet; 2003 May; 72(5):1293-9. PubMed ID: 12690580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dimerization is required for GARS-mediated neurotoxicity in dominant CMT disease.
    Malissovas N; Griffin LB; Antonellis A; Beis D
    Hum Mol Genet; 2016 Apr; 25(8):1528-42. PubMed ID: 27008886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aminoacyl-tRNA synthetases and tRNAs in human disease: an introduction to the JBC Reviews thematic series.
    Musier-Forsyth K
    J Biol Chem; 2019 Apr; 294(14):5292-5293. PubMed ID: 30799306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alternative stable conformation capable of protein misinteraction links tRNA synthetase to peripheral neuropathy.
    Blocquel D; Li S; Wei N; Daub H; Sajish M; Erfurth ML; Kooi G; Zhou J; Bai G; Schimmel P; Jordanova A; Yang XL
    Nucleic Acids Res; 2017 Jul; 45(13):8091-8104. PubMed ID: 28531329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The GARS gene is rarely mutated in Japanese patients with Charcot-Marie-Tooth neuropathy.
    Abe A; Hayasaka K
    J Hum Genet; 2009 May; 54(5):310-2. PubMed ID: 19329989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Charcot-Marie-Tooth disease and related inherited neuropathies.
    Murakami T; Garcia CA; Reiter LT; Lupski JR
    Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.
    Mersiyanova IV; Perepelov AV; Polyakov AV; Sitnikov VF; Dadali EL; Oparin RB; Petrin AN; Evgrafov OV
    Am J Hum Genet; 2000 Jul; 67(1):37-46. PubMed ID: 10841809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Antiepileptic Valproic Acid Ameliorates Charcot-Marie-Tooth 2W (CMT2W) Disease-Associated HARS1 Mutation-Induced Inhibition of Neuronal Cell Morphological Differentiation Through c-Jun N-terminal Kinase.
    Memezawa S; Sato T; Ochiai A; Fukawa M; Sawaguchi S; Sango K; Miyamoto Y; Yamauchi J
    Neurochem Res; 2022 Sep; 47(9):2684-2702. PubMed ID: 35380399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical characteristics and proteome modifications in two Charcot-Marie-Tooth families with the AARS1 Arg326Trp mutation.
    Høyer H; Busk ØL; Esbensen QY; Røsby O; Hilmarsen HT; Russell MB; Nyman TA; Braathen GJ; Nilsen HL
    BMC Neurol; 2022 Aug; 22(1):299. PubMed ID: 35971119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conformational sampling of CMT-2D associated GlyRS mutations.
    Childers MC; Regnier M; Bothwell M; Smith AST
    Brain Multiphys; 2022; 3():. PubMed ID: 36504507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss-of-function alanyl-tRNA synthetase mutations cause an autosomal-recessive early-onset epileptic encephalopathy with persistent myelination defect.
    Simons C; Griffin LB; Helman G; Golas G; Pizzino A; Bloom M; Murphy JL; Crawford J; Evans SH; Topper S; Whitehead MT; Schreiber JM; Chapman KA; Tifft C; Lu KB; Gamper H; Shigematsu M; Taft RJ; Antonellis A; Hou YM; Vanderver A
    Am J Hum Genet; 2015 Apr; 96(4):675-81. PubMed ID: 25817015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel multisystem disease associated with recessive mutations in the tyrosyl-tRNA synthetase (YARS) gene.
    Nowaczyk MJ; Huang L; Tarnopolsky M; Schwartzentruber J; Majewski J; Bulman DE; ; Hartley T; Boycott KM
    Am J Med Genet A; 2017 Jan; 173(1):126-134. PubMed ID: 27633801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.